All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Axi-cel vs SoC for R/R LBCL: ZUMA-7 primary analysis

Feb 24, 2022
Share:
Learning objective: After viewing this visual abstract, learners will be able to recall key safety and efficacy data from the phase III ZUMA-7 trial evaluating axi-cel versus SoC second-line therapy in adult patients with R/R large B-cell lymphoma.

The Lymphoma Hub is happy to present a Visual Abstract representing key data from the primary analysis of the phase III ZUMA-7 study (NCT03391466), evaluating the clinical efficacy of axicabtagene ciloleucel versus standard-of-care second-line therapy in adult patients with relapsed/refractory large B-cell lymphoma.


 

To download this visual abstract, click below!

Download here

Visual Abstract

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you